List of Excipients in Branded Drug BERKLEY AND JENSEN ANTI DIARRHEAL

Generic Drugs Containing BERKLEY AND JENSEN ANTI DIARRHEAL

Company	Ingredient	NDC	Excipient
BJWC	loperamide hydrochloride	68391-224	ANHYDROUS LACTOSE
BJWC	loperamide hydrochloride	68391-224	CARNAUBA WAX
BJWC	loperamide hydrochloride	68391-224	CELLULOSE, MICROCRYSTALLINE
BJWC	loperamide hydrochloride	68391-224	D&C YELLOW NO. 10 ALUMINUM LAKE
BJWC	loperamide hydrochloride	68391-224	FD&C BLUE NO. 1 ALUMINUM LAKE
BJWC	loperamide hydrochloride	68391-224	HYPROMELLOSE

What are the Most Frequently-Used Excipients in BERKLEY AND JENSEN ANTI DIARRHEAL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10 ALUMINUM LAKE
1	FD&C BLUE NO. 1 ALUMINUM LAKE
1	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for Berkley and Jensen Anti-Diarrheal

Last updated: February 26, 2026

What are the key excipient considerations for Berkley and Jensen Anti-Diarrheal?

The formulation of Berkley and Jensen Anti-Diarrheal, which primarily contains loperamide, requires excipients that ensure stability, bioavailability, and consumer acceptability. Standard excipients in anti-diarrheal products include coating agents, binders, disintegrants, fillers, and flavoring agents.

Typical excipient roles:

• Fillers: Microcrystalline cellulose, lactose, or dibasic calcium phosphate support tablet mass.
• Disintegrants: Crospovidone or sodium starch glycolate ensure rapid dissolution.
• Binders: Hydroxypropyl methylcellulose or povidone provide tablet integrity.
• Coatings: Hypromellose-based coatings control release and mask taste.
• Flavoring: Menthol or artificial fruit flavors improve patient compliance.

Formulation challenges:

• Stability of active ingredient (loperamide hydrochloride) in presence of moisture.
• Ensuring controlled release to prevent spikes in plasma concentration.
• Masking bitter taste of active ingredient.

What are the commercial opportunities linked to excipient choices?

Choosing specific excipients influences product differentiation, patenting opportunities, manufacturing costs, and consumer acceptance.

Differentiation potential

• Controlled-release formulations: Using hydrophilic polymers like ethylcellulose enables sustained release, reducing dosing frequency. This can justify premium pricing.
• Taste-masking technologies: Employing lipid- or polymer-based taste-masking excipients enhances consumer appeal.
• Novel excipients: Incorporation of plant-based or allergen-free excipients aligns with clean-label trends, appealing to health-conscious consumers.

Market size implications

The global anti-diarrheal market was valued at approximately $2.9 billion in 2021, projected to grow at 6% annually through 2028 (Grand View Research). Formulation innovations around excipients can capture increased demand, especially in developed and emerging markets.

Patent and regulatory considerations

• Patenting unique excipient combinations or controlled-release technologies provides competitive barriers.
• Regulatory trends favor excipients with well-documented safety profiles (GRAS status in U.S.).

Cost considerations

• High-quality excipients increase manufacturing costs but improve product stability and consumer perception.
• Bulk procurement and supplier negotiations can optimize costs without compromising quality.

How does excipient choice impact manufacturing and supply chains?

Excipients affect process robustness, scalability, and supply chain stability.

• Physicochemical stability: Excipients should have consistent source quality and stability under manufacturing conditions.
• Compatibility: Selected excipients must not interact adversely with the active pharmaceutical ingredient (API).
• Global supply chains: Diversifying suppliers minimizes risks from geopolitical or logistics disruptions.
• Regulatory compliance: Input from suppliers should include comprehensive documentation (certificates of analysis, safety data sheets).

What are current regulatory standards influencing excipient use?

Regulatory authorities such as the FDA and EMA emphasize:

• Use of excipients with documented safety profiles.
• Full disclosure on labeling regarding excipient origins and potential allergens.
• Validation of manufacturing processes to ensure batch-to-batch consistency.

What are the emerging trends and future outlook?

• Biodegradable and plant-derived excipients: Respond to consumer demand for natural and sustainable products.
• Personalized medicine approaches: Formulation adjustments via excipients tailored to specific populations.
• Advanced delivery systems: Incorporating nanotechnology-enabled excipients for targeted release.

Key Takeaways

• Excipient selection in Berkley and Jensen Anti-Diarrheal impacts stability, efficacy, taste, and consumer acceptance.
• Differentiation through controlled-release and taste-masking excipients can generate a competitive edge.
• Strategic sourcing and regulatory compliance influence manufacturing costs and supply chain resilience.
• Innovation with natural and biodegradable excipients aligns with market trends.
• Patent protection around unique excipient combinations enhances market exclusivity.

FAQs

1. What excipients are most critical for anti-diarrheal formulations?
   Fillers, disintegrants, binders, coatings, and flavoring agents.

2. Can excipient modifications extend product patent life?
   Yes, innovative combinations or delivery mechanisms involving excipients can be patented.

3. Are there risks associated with natural excipients?
   Synthetic and natural excipients must meet safety standards; natural sources can introduce variability.

4. How do excipients influence drug pricing?
   High-quality excipients increase costs but may justify premium pricing due to improved product features.

5. What future excipient trends will impact anti-diarrheal products?
   Increased use of biodegradable, plant-based, and nanotechnology-enabled excipients.

References

[1] Grand View Research. (2022). Anti-diarrheal drugs market size, share & trends analysis.
[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in solid oral dosage forms.